“Diversity in clinical trials is not only an ethical imperative; it is also good science. It allows us to understand how treatments affect different populations and how we can solve these differences,” said Estelamari Rodriguez, MD.

May 9, 2024 · Proteus mirabilis is a Gram-negative bacterium in the Enterobacteriaceae family that frequently causes urinary tract infections (UTIs). 1 It often causes infections in patients with long-term catheterization due to its ability to swarm across surfaces (swarming motility), its production of urease, and its ability to form biofilms. 2 The increasing incidence of antibiotic resistance can ...

Aug 18, 2023 · Updated guidelines cover preferred treatment options for AMR gram-negative infections, including ESBL-E, AmpC-E, CRE, DTR-P aeruginosa, CRAB, and S maltophilia.

Dec 5, 2022 · The list of potential causes of fever and rash (also called pyrexia or febrile illness) is lengthy. It includes viruses, bacteria, spirochetes, rickettsiae, medications, and rheumatologic diseases, among other potential causes. 1 Fever and Rash Causes & Risk Factors

Sep 20, 2024 · For uncomplicated ESBL-producing cystitis, amoxicillin-clavulanic acid continues to not be a preferred agent; however, there may be occasions such that it is prescribed if resistance or toxicities preclude alternative oral antibiotic use and there is a preference to avoid intravenous antibiotics.

Feb 27, 2025 · The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval.

2 days ago · A Prescription Drug User Fee Act target date of June 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as pre-exposure ...

Feb 24, 2025 · Certain antiviral drugs and monoclonal antibody (mAb) therapies continue to lower mortality risk and reduce hospitalization among individuals infected with the SARS-CoV-2 Omicron variant and certain Omicron subvariants, according to systematic review and meta-analysis study findings published in Influenza and Other Respiratory Viruses.. Investigators estimated the comparative effectiveness of ...

Aug 23, 2024 · Risk Assessment. For adults with complicated IAI, the panel recommends the APACHE II (Acute Physiology Age Chronic Health Evaluation II) as the preferred measurement scale for risk stratification within 24 hours of hospital or intensive care unit (ICU) admission (low certainty of evidence).

Jan 31, 2025 · Referring patients who present to the emergency department (ED) with bacteremia to an infectious disease physician is the only modifiable strategy to decrease 28-day mortality with long-term effect, according to study results published in BMC Infectious Diseases.. Researchers conducted a retrospective cohort study at the Jewish General Hospital in Montreal, Quebec to identify areas for ...